Roche HPV assay
This article was originally published in The Gray Sheet
Executive Summary
FDA initiates dialogue with company over classification of HPV assay as analyte-specific reagent, according to Roche, which said it plans to meet with agency officials within days. In November, FDA informed the firm that the AmpliChip microarray requires clearance prior to marketing and cannot be offered to labs as an ASR for determining drug metabolization rates. Roche has removed all information pertaining to the HPV test from its website, including a release citing claims by Jane Gibson, PhD, that the product could be more sensitive than hybrid capture technology currently on the market (1"The Gray Sheet" March 1, 2004, In Brief)...
You may also be interested in...
Roche Amplicor HPV test
Roche study comparing Amplicor with Digene's Hybrid Capture 2 test suggests Amplicor may be more sensitive, according to Jane Gibson, PhD, molecular genetics director at the AmeriPath Center for Advanced Diagnostics in Orlando. Presented at the 21st International Papillomavirus Conference in Mexico City, the results reveal an HPV-positive rate of 15.1% with Amplicor and 9.3% with the HC2 test. The presence of high-risk HPV was confirmed in 33% of Amplicor positive/HC2 negative specimens. Roche plans to complete U.S. clinical trials of the polymerase-chain reaction test by Q2 2005 (1"The Gray Sheet" Feb. 9, 2004, p. 14)...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.